A European consensus statement says antithrombotic treatment for acute coronary syndromes should adjust for sex differences ...

Aurobindo Pharma shares fell nearly 5% to ₹1,039 amid reports it may acquire Zentiva for $5-5.5 billion. This would be the ...

Aurobindo Pharma shares fell 4.67 per cent to hit a high of Rs 1,039.30 on BSE, commanding a market capitalisation of just ...

Reports suggested it has emerged as the frontrunner to acquire Prague-based Zentiva for $5 to $5.5 billion. If completed, this would be the largest-ever acquisition by an Indian pharma company.

DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the ...

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Tokyo stocks reached all-time highs for a second consecutive day and for the fourth time in six trading days, and then ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...